Book a demo
Topics · REGULATORY

Healthcare Payors Model Risk Build vs Buy | Moring

The build-versus-buy question for payor model risk is not whether to govern models but who operates the governance machinery. Building offers control and fit to payor-specific workflows at the cost of scarce specialist capacity; buying offers mature inventory, validation, and monitoring capability that must be adapted to payor decision rights. Most payors buy the platform and build the accountability.

On this page
  1. Short answer
  2. How it works
  3. FAQs
  4. Related reading
  5. Sources

Short answer

The build-versus-buy question for payor model risk is not whether to govern models but who operates the governance machinery. Building offers control and fit to payor-specific workflows at the cost of scarce specialist capacity; buying offers mature inventory, validation, and monitoring capability that must be adapted to payor decision rights. Most payors buy the platform and build the accountability.

How it works

Most payors asking this question already know they need model risk management; the decision is about the machinery. Governance requires an inventory, risk assessment, validation workflows, compliance mapping, monitoring, and vendor oversight. Building all of that in-house is a multi-year platform effort competing with the payor's core technology agenda, while buying imports machinery that was designed for someone else's organization. The honest comparison starts by naming what each side actually provides. It also starts by sizing the real volume: a payor with a dozen models faces a different decision from one with hundreds.

The build case rests on fit and control. Payor model risk has specifics that generic tooling may not express: utilization management review cycles, coverage policy linkage, clinical evidence standards, and the segregation between business acceptance and independent validation. A homegrown system can encode those precisely, integrate with existing claims and credentialing infrastructure, and keep every record inside payor infrastructure. The cost is sustained specialist capacity that few payor technology organizations can dedicate, and studies of healthcare governance frameworks consistently note that resource requirements create barriers even for well-resourced institutions. Attrition is the quieter build risk, since a homegrown system maintained by one strong engineer becomes fragile the day that engineer leaves.

The buy case rests on maturity and speed. Purpose-built governance platforms now cover the core capability set: inventory, risk assessment, compliance mapping, cross-functional workflows, regulatory tracking, and vendor oversight. Buying obtains those functions immediately and inherits their evolution, which matters because external expectations are moving. The tradeoff is adaptation: platform workflows must be configured to the payor's decision rights, and a tool that arrives with its own assumptions about who approves what will either be reshaped or, more dangerously, quietly dictate the organization's governance model.

The realistic answer for most payors is a split. Buy the machinery that is commodity: inventory, monitoring, evidence collection, workflow routing. Build the parts that encode accountability: risk tiering criteria tied to payor use cases, validation standards for models influencing coverage decisions, and the decision-rights matrix that says who may deploy and approve what. Governance platforms can enforce that structure, but the structure itself is organizational and does not come from software. A useful test is whether the payor can state its decision rights before opening the vendor's configuration screens.

Due diligence on the buy side should mirror the payor's own control expectations. Ask vendors how the platform handles identity and access, where evidence is stored, how it supports an audit trail for model changes, and how it maps to obligations such as the EU AI Act. A platform that cannot demonstrate its own governance will not strengthen the payor's. Requesting a walkthrough of the vendor's own audit trail is a faster test than any questionnaire.

Whatever the split, keep the accountability local. Model risk at a payor is ultimately about the defensibility of coverage decisions, and neither a homegrown tool nor a purchased platform supplies defensibility; they supply the containers for it. The payor builds the judgment, validates on its own populations, and names its approvers, and the build-versus-buy decision only determines how much of the plumbing it had to write itself.

Hybrid arrangements deserve attention beyond the simple split. Some payors buy the platform and integrate their own validation workflows into it; others run a purchased inventory layer while keeping validation evidence in existing quality systems. Contracts can be structured around this reality, with the platform scoped to specific capabilities rather than to a grand mandate. The critical discipline in any hybrid is interface clarity: which system is the system of record for the inventory, which for validation status, and which for approvals. Ambiguity there produces the worst outcome, two systems that disagree, and the disagreements surface exactly when an auditor asks a question both systems answer differently. Define the record roles in writing before configuration begins.

Frequently asked questions

What is the real question behind build versus buy for model risk?

Who operates the governance machinery, not whether governance exists. Inventory, validation workflows, monitoring, and evidence collection are commodity capabilities that purpose-built platforms now cover, while risk tiering criteria, validation standards, and decision rights are organizational choices no vendor can supply. Most payors buy the platform and build the accountability structure inside it.

What is the strongest argument for building model risk tooling in-house?

Fit to payor specifics. Utilization management review cycles, coverage policy linkage, clinical evidence standards, and the separation of business acceptance from independent validation are payor-specific, and a homegrown system can encode them exactly while integrating with existing claims and credentialing infrastructure. The cost is sustained specialist capacity that few payor technology organizations can dedicate over years.

What should payors verify when evaluating a governance platform vendor?

The vendor's own controls: how the platform handles identity and access, where evidence is stored, whether it supports a complete audit trail for model changes, and how it maps to obligations such as the EU AI Act. A platform that cannot demonstrate its own governance will not strengthen the payor's, so due diligence should apply the same standard the payor applies to itself.

Can a purchased platform impose governance a payor did not choose?

Yes, quietly. Platforms ship with assumptions about workflows and approvals, and if the payor does not configure its own decision rights explicitly, the tool's defaults become the organization's governance model by inertia. That is why the build side of the split, defining tiering criteria, validation standards, and approver roles, should be settled before configuration begins.

Sources

  1. nist.gov
  2. pmc.ncbi.nlm.nih.gov
  3. adaptivesecurity.com
  4. hitrustalliance.net
  5. trustible.ai
  6. himss.org
  7. forvismazars.us
  8. crowell.com
  9. - artificialintelligenceact.eu